IL-1β does not cause neutrophil degranulation but does lead to IL-6, IL-8, and nitrite/nitrate release when used in patients with cancer

Journal of Immunology

Volumn 156, Issue 1, 1996, Pages 389-394

  Ogilvie, Aernout C ^a   Hack, C Erik ^a,c   Wagstaff, John ^c   Van Mierlo, Gerard J ^b   Eerenberg, Anke J M ^b   Thomsen, Lindy L ^d   Hoekman, Klaas ^c   Rankin, Elaine M ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d WELLCOME RESEARCH LABORATORIES   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C4B; ELASTASE; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; LACTOFERRIN; NITRATE; NITRITE; RECOMBINANT INTERLEUKIN 1BETA; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CARDIOTOXICITY; CHILL; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPLEMENT ACTIVATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG FORMULATION; FEMALE; HEADACHE; HUMAN; HUMAN CELL; INFLAMMATION; INTRAVENOUS DRUG ADMINISTRATION; MALAISE; MALE; MELANOMA; METASTASIS; MYALGIA; NEUTROPHIL; NEUTROPHILIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

ADULT; ANTINEOPLASTIC AGENTS; CELL DEGRANULATION; COMPLEMENT ACTIVATION; FEMALE; HUMANS; INTERLEUKIN-1; INTERLEUKIN-6; INTERLEUKIN-8; LEUKOCYTE COUNT; MALE; MELANOMA; MIDDLE AGED; NEUTROPHILS; NITRATES; NITRITES;

EID: 0029671325     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Dinarello, C A. 1991. Interleukin-1 and interleukin-1 antagonism. Blood 77: 1627.
2. Nemunaitis, J., F R. Appelbaum, K. Lilleby, W C Buhles, C. Rosenfeld, Z Zeigler, R K. Shadduck, J W Singer, W. Meyer, and C D. Buckner 1994. Phase I study of recombinant interleukin-1β in patients undergoing autologous bone marrow transplantation for acute myelogenous leukemia. Blood 83 3473
3. Wheeler, R. H , R F. Meredith, M. N Saleh, M. B Khazaeli, J. L Murray, and A F. LoBuglio 1994 A phase II trial of IL-1 + radioimmunotherapy in patients with metastatic colon cancer Proc Am. Soc. Clin. Oncol 13:295 (Abstr).
4. Schuchter, L , D Neuberg, M. Atkins, B Tester, A Reclo, C. Sickies, J Moore, B Light, T. Anderson, A. Chachouos, and J. Dutcher 1994 A phase 1 study of interleukin-1α and high-dose cyclophosphamide in patients with advanced cancer Proc. Am Soc Clin. Oncol. 13 133 (Abstr.).
5. Crown, J., A Jabukowski, N Kemeny, M. Gordon, C. Gasparetto, G. Wong, C. Sheridan, G Toner, B. Meisenberg, J Botet J Applewhite, S Sinha, M. Moore, D Kelsen, J Buhles, and J Gabrilove. 1991. A phase 1 trial of recombinant human interleukin-1β alone and in combination with myelosuppressive doses of 5-fluorouracil in patients with gastrointestinal cancer. Blood 78: 1420.
6. Smith, I., D. L. Longo, G. Alvord, J. E. Janik, W. H Sharfman, B. L. Gause, B. D Curti, S. P. Creckmore, J. T. Holmlund, R. G. Fenton, M. Sznol, L. L. Miller, M. Shimizu, J. J. Oppenheim, S. J. Fiem, J C. Hursey, G. C. Powers, and W. J. Urba. 1993. The effects of treatment with interleukin-1α on platelet recovery after high-dose carboplatin. N. Engl J. Med 328:756.
7. Vadhan-Raj, S., A. P. Kudelka, L. Garrison, J Gano, C. L. Edwards, R. S. Freedman, and J. J. Kavanagh. 1994. Effects of interleukin-1α on carboplatin-induced thrombocytopenia in patients with recurrent ovarian cancer. J. Clin. Oncol. 12: 707.
8. Steis, R., I. Smith, J. Janik, R Fenton, W. Sharfman, J. Rossio, W. Kopp, W. Buhles, F. Ruscetti, J Keller, D. Longo, K. Hestdal, N Wells, and W. Urba 1991 Phase I study of recombinant IL-1β (Syntex). Proc. Am Soc. Clin. Oncol. 10:211 (Abstr.).
9. Starnes, H. F , G Hartman, F. Torti, R. W. Carlson, A Tewari, and W C Buhles. 1991. Recombinant human interleukin-1β has antitumor activity and acceptable toxicity in metastatic malignant melanoma. Proc. Am. Soc Clin. Oncol. 10:292 (Abstr.).
10. Smith, I , W. J. Urba, B. D. Curti, L. J. Elwood, R G. Steis, J. E. Janik, W. H. Sharfman, L. L. Miller, R. G. Fenton, K C. Conlon, M. Sznol, S. P Creekmore, N. F. Wells, F. W. Ruscetti, J. R. Keller, K. Hestdal, M. Shimizu, J Rossio, W. G. Alvord, J. J. Oppenheim, and D L. Longo. 1992. The toxic and hematologic effects of interleukin-1α administered in a phase I trial to patients with advanced malignancies. J. Clin. Oncol. 10:1141.
11. Wilson, W. H., G Bryant, M Fox, L. Miller, S. Steinberg, B. Goldspiel, W. Urba, J. O'Shaunghnessy, J. Smith, and R Wittes. 1993. Interleukin-1α administered before high-dose ifosfamide, CBDCA, and etoposide with autologous bone marrow rescue shortens neutrophil recovery. Proc. Am. Soc. Clin. Oncol. 12:289 (Abstr.).
12. Nemunaitis, J., M. Ross, B Meisenberg, R O'Reilly, K. Lilleby, C. D Buckner, F. R. Appelbaum, W Buhles, J. Singer, and W. P. Peters. 1994. Phase I study of recombinant human interleukin-1β in patients with bone marrow failure. Bone Marrow Transplant. 14:583
13. Redman, B. G , Y. Abubakr, T. Chou, P. Esper, and L. E. Flaherty. 1994. Phase II trial of recombinant interleukin-1β in patients with metastatic renal cell carcinoma. J. Immunother. 16:211 (Abstr.).
14. van der Poll, T., S. J. H. van Deventer, C. E. Hack, G. J. Wolbink, L. A Aarden, H. R. Büller, and J. W. ten Cate 1992 Effects on leukocytes after injection of tumor necrosis factor into healthy humans. Blood 79:693.
15. van Deventer, S. J. H , M. Hart, T. van der Poll, C E Hack, and L A Aarden. 1993. Endotoxin and tumor necrosis factor-α-induced interleukin-8 release in humans J. Infect. Dis. 167:461.
16. Selby, P., S. Hobbs, C. Viner, E. Jackson, A Jones, D. Newell, A. H Calvert, T McElwain, K. Fearon, J Humphreys, and T Shiga. 1987. Tumor necrosis factor in man: clinical and biological observations. Br. J. Cancer 56:803.
17. Kilbourn, R. G., S S. Gross, A. J. Jubran, J. Adams, O. W. Griffith, R. Levi, and R. F. Lotado. 1990. N,G-Methyl-L-arginine inhibits tumor necrosis factor-induced hypotension, implications for the involvement of nitric oxide. Proc. Natl. Acad Sci. USA 87:3629.
18. Ikejima, T., S. Okusawa, P Ghezzi, J W. M. van der Meer, and C. A Dinarello. 1990. Interleukin-1 induces tumor necrosis factor (TNF) in human peripheral blood mononuclear cells in vitro and a circulating TNF-like activity in rabbits. J. Infect. Dis. 162:215.
19. van Zee, K. J., L. E DeForge, E. Fischer, M. A. Marano, J. S. Kenney, D. G. Remick, S. L. Lowry, and L. L. Moldawer 1991. Interleukin-8 in septic shock, endotoxemia, and after interleukin-1 administration. J. Immunol. 146 3478.
20. Buescher, E S., S. M. McIlheran, S. M. Banks, A. P. Kudelka, J. J. Kavanagh, and S. Vadhan-Raj. 1993 The effects of interleukin-1 therapy on peripheral blood granulocyte function in humans. Cancer Immunol. Immunother. 37:26.
21. w-amino-L-arginine. Proc. Natl. Acad. Sci. USA 84. 1008
22. 2 in sepsis Studies in nonhuman primates following interleukin-1α administration and during lethal bacteremia. Blood. 86.1027
23. Helle, M., L. Boeije, E. R. de Groot, A. de Vos, and L. A Aarden. 1991. Sensitive ELISA for interleukin-6. Detection of IL-6 in biologic fluids: synovial fluids and sera J. Immunol. Methods 138:47.
24. Hack, C. E., M. Hart, R. J. M Strack van Schijndel, A. I. M Eerenberg, J H. Nutjens, L. G. Thijs, and L. A. Aarden 1992. Interleukin-8 in sepsis: relation to shock and inflammatory mediators. Infect. Immun. 60:2835.
25. Thomsen, L. L., B. C. Baguley, G. J. S. Rustin, and S. M. O'Reilly 1992. Flavone acetic acid with recombinant interleukin-2 in advanced malignant melanoma. II. induction of nitric oxide production. Br. J. Cancer 66:723.
26. 15N]nitrate in biologic fluids. Anal. Biochem. 126:131
27. Miles, D., L Thomsen, F. Balkwill, P Thavasu, and S. Moncada. 1994. Association between the biosynthesis of nitric oxide and changes in immunologic and vascular parameters in patients treated with interleukin-2. Eur. J. Clin. Invest. 24:287.
28. 125I-C3a. J. Immunol. Methods 108:77.
29. Hack, C. E., J. Paardekooper, R. J. T. Smeenk, J. J. Abbink, A. J. M. Eerenberg, and J. H. Nuijens 1988. Disruption of the internal thioester bond in the third component of complement (C3) results in the exposure of neodeterminants also present on activation products of C3: an analysis with monoclonal antibodies. J. Immunol. 141:1602.
30. Nuijens, J. H , J. J. Abbink, Y. T. Wachtfogel, R. W. Colman, A. J. M Eerenberg, D. Dors, A. J M. Kamp, R. J. M. Strack van Schijndel, L. G. Thijs, and C E Hack. 1992. Plasma elastase α1-antitrypsin and lactoferrin in sepsis: evidence for neutrophils as mediators in fatal sepsis. J. Lab. Clin. Med. 119:159.
31. Kilbourn, R. G., and P. Belloni. 1990. Endothelial cell production of nitrogen oxides in response to interferon-γ, in combination with rumor necrosis factor, interleukin-1, or endotoxin. J. Natl. Cancer Inst. 82:772.
32. Moncada, S , and A. Higgs. 1993. The L-arginine-nitric oxide pathway. N Engl. J. Med. 329:2002.
33. 2 Circulation 89:2266.
34. van Deventer, S. J. H., H. R. Büller, J. W. ten Cate, L. A. Aarden, C. E. Hack, and A. Sturk. 1990. Experimental endotoxaemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood 76:2520.
35. Baars, J W., C. E. Hack, J. Wagstaff, A. J. M. Eerenberg-Belmer, G J. Wolbink, L. G. Thijs, R. J. M. Strack van Schijndel, H L. J. A van der Vall, and H. M. Pinedo 1992. The activation of polymorphonuclear neutrophils and the complement system during immunotherapy with recombinant interleukin-2. Br. J. Cancer 65:96.
36. Sims, J E., J. G. Giri, and S. K. Dower 1994. The two interleukin-1 (IL-1) receptors play different roles in IL-1 actions. Clin. Immunol. Immunupathol. 72 9.
37. Borish, L., R Rosenbaum, L. Albury, and S. Clark. 1989. Activation of neutrophils by recombinant interleukin-6. Cell. Immunol. 121:280.
38. Matsushima, K., and J J Oppenheim. 1989. Interleukin-8 and MCAF, novel inflammatory cytokines inducible by interleukin-1 and tumor necrosis factor. Cytokine 1:2.
39. Schröder, J. M., N. L M. Persoon, and E. Christophers. 1990. Lipopolysaccharide-stimulated human monocytes secrete, apart from neutrophil activating peptide-1/interleukin-8, a second activating protein. J. Exp. Med. 171:1091.
40. Detmers, P. A., S K. Lo, E. Olsen-Egbert, A. Walz, M. Baggiolini, and Z. A Conn. 1990. Neutrophil-activating protein-1/interleukin-8 stimulates the binding activity of the leukocyte adhesion receptor CD11b/CD18 on human neutrophils J. Exp Med. 171.1155
41. Smith, W. B , J. R. Gamble, I. Clark-Lewis, and M. A Vadas 1991. Interleukin-8 induces neutrophil transendothelial migration Immunology 72:65.